Key facts
- This page summarizes Douglas Liu's Form 4 filing for Talis Biomedical Corp.
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 05 Oct 2021, 16:49.
Douglas Liu - 02 Oct 2021 Form 4 Insider Report for Talis Biomedical Corp
- Reporting relationship
- Chief Operating Officer
- Issuer ticker
- N/A
- Reported as of
- 02 Oct 2021
- Net transaction value
- $0
- Reporting owner signature
- /s/ Karen E. Flick, Attorney-in-Fact for Douglas Liu
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Douglas Liu filed Form 4 for Talis Biomedical Corp on 05 Oct 2021.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
TLIS
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- Shares
- +200,000
- Change %
- +64%
- Price
- Shares after
- 514,685
- Date
- 02 Oct 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 200,000
- Exercise price
- $6.17
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
25% of the shares underlying this option shall vest on the first annual anniversary of the vesting commencement date and 1/48th of the shares underlying this option shall vest monthly thereafter over 36 months.
Footnote F2
Price not required on initial report of stock option granted.